COMPARISON

Ciclosporin vs DSIP

5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.

Answer

Ciclosporin is authorised or registered in 9 and DSIP in 0 of the 10 registers read. Ciclosporin: highest phase Phase 4 (after approval). DSIP: No trial states a phase. 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

CiclosporinDSIP
Registered trials
differs
1328
clinicaltrials.gov · 2026-10-03
1
clinicaltrials.gov · 2026-10-03
FDA label
differs
FDA label, application not recorded: VEVYE
openfda · 2026-08-31T07:37:14Z
Not checked
no record of "fdaLabel" for dsip
EU authorisation
differs
Authorised
ema · 2026-10-03
Nothing on record
ema read 2026-08-31
EU authorised on
differs
2015-03-19
ema · 2026-10-03
Not checked
no record of "authorisedOn" for dsip
ATC code
differs
S01XA18
ema · 2026-10-03
Not checked
no record of "atcCode" for dsip

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectCiclosporinplaceboDSIPplacebo
Punctate Keratitis5.8%4.5%--

Trial register Ciclosporin: 7 placebo-controlled trials; DSIP: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Ciclosporin side effects · DSIP side effects

LEGAL STATUS

Approval in each country read

CountryCiclosporinDSIPRegister
United StatesFDA label, application not recordedNot on the registerRegulator FDA
European UnionAuthorisedNot on the registerRegulator EMA
United KingdomAuthorisedNot on the registerRegulator MHRA
CanadaAuthorisedNot on the registerRegulator Health Canada
AustraliaRegisteredStatus unknownRegulator TGA
SwitzerlandAuthorisedNot on the registerRegulator Swissmedic
BrazilRegistadoNot on the registerRegulator ANVISA
SerbiaAuthorisedNot on the registerRegulator ALIMS
SingaporeRegisteredNot on the registerRegulator HSA
TurkeyRuhsatliNot on the registerRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.